Metamizole
Phase 3Small molecule
Boehringer IngelheimMetamizole is one of 23 small molecule programs targeting Cancer Pain. It is currently in Phase 3.
1
Indications
12
Total Trials
2
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Cancer Pain
#DrugCompanyPhaseTrials
1Duragesic
CCephalon
Approved
Oxycontin
PProtega
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
Marinol
Jazz PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Suboxone
IIndivior Inc.
Approved
Tylenol
KKenvue Brands
Approved
Spravato
WWim Janssens
Approved
Advil
KKenvue Brands
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment2 trials
Oncology Patients1 trial
6 more indications
Analgesia1 trial
Post Operative Pain1 trial
Postoperative Pain in Scheduled Craniotomy
Completed·—··NCT04720248·73 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metamizole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company